Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection, and autoimmune disease, today announced new preclinical data for AB248, its CD8-targeted interleukin-2 (IL-2) immunotherapy, and for AB821, its CD8-targeted interleukin-21 (IL-21)...

Click to view original post